Resource Summary Report

Generated by RRID on Aug 29, 2026

A549-ACE2

RRID:CVCL_C0Q5
Type: Cell Line

Proper Citation

RRID:CVCL_C0Q5

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_C0Q5

Proper Citation: RRID:CVCL_C0Q5

Description: Cell line A549-ACE2 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung adenocarcinoma

Defining Citation: PMID:33208793

Comments: Population: Caucasian., Group: SARS-CoV-2 research cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: A549-ACE2

Synonyms: A549-Ace2

Cross References: cancercelllines:CVCL_C0Q5, GEO:GSM5224710, GEO:GSM5224711, GEO:GSM5224712, PRIDE:PXD019645, PRIDE:PXD023418, Wikidata:Q112927063

ID: CVCL_C0Q5

Hierarchy: cvcl_0023

Record Creation Time: 20220624T070150+0000

Record Last Update: 20260816T000250+0000

Ratings and Alerts

No rating or validation information has been found for A549-ACE2.

No alerts have been found for A549-ACE2.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 125 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

El Kamali L, et al. (2026) Comprehensive investigation of SARS-CoV-2 intestinal pathogenesis in Drosophila. iScience, 29(5), 115621.

Ferjancic Z, et al. (2024) Development of iminosugar-based glycosidase inhibitors as drug candidates for SARS-CoV-2 virus via molecular modelling and in vitro studies. Journal of enzyme inhibition and medicinal chemistry, 39(1), 2289007.

Venet M, et al. (2023) Severe COVID-19 patients have impaired plasmacytoid dendritic cell-mediated control of SARS-CoV-2. Nature communications, 14(1), 694.

Nair MS, et al. (2023) SARS-CoV-2 omicron variants are susceptible in vitro to Artemisia annua hot water extracts. Journal of ethnopharmacology, 308, 116291.

Lohse ZM, et al. (2023) Persistence of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant in Children and Utility of Rapid Antigen Testing as an Indicator of Culturable Virus. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 76(3), e491.

Asiedu SO, et al. (2023) Mycolactone: A Broad Spectrum Multitarget Antiviral Active in the Picomolar Range for COVID-19 Prevention and Cure. International journal of molecular sciences, 24(8).

Alhammad YM, et al. (2023) SARS-CoV-2 Mac1 is required for IFN antagonism and efficient virus replication in mice. bioRxiv : the preprint server for biology.

Tan KS, et al. (2023) SARS-CoV-2 Omicron variant shedding during respiratory activities. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 131, 19.

Mohammad TSH, et al. (2023) In Silico Binding of 2-Aminocyclobutanones to SARS-CoV-2 Nsp13 Helicase and Demonstration of Antiviral Activity. International journal of molecular sciences, 24(6).

Wang C, et al. (2023) Identification and characterization of 7-azaindole derivatives as inhibitors of the SARS-CoV-2 spike-hACE2 protein interaction. International journal of biological macromolecules, 244, 125182.

Yao Y, et al. (2023) RBM24 inhibits the translation of SARS-CoV-2 polyproteins by targeting the 5'-untranslated region. Antiviral research, 209, 105478.

Thaweerattanasinp T, et al. (2023) SARS-CoV-2 Delta (B.1.617.2) variant replicates and induces syncytia formation in human induced pluripotent stem cell-derived macrophages. PeerJ, 11, e14918.

Dong W, et al. (2023) Factor Xa cleaves SARS-CoV-2 spike protein to block viral entry and infection. Nature communications, 14(1), 1936.

Luo SY, et al. (2023) Identification of Human Host Substrates of the SARS-CoV-2 Mpro and PLpro Using Subtiligase N-Terminomics. ACS infectious diseases, 9(4), 749.

Kelch MA, et al. (2023) Machine learning on large scale perturbation screens for SARS-CoV-2 host factors identifies ?-catenin/CBP inhibitor PRI-724 as a potent antiviral. Frontiers in microbiology, 14, 1193320.

Xiao Y, et al. (2023) CDK4/6 inhibitor palbociclib promotes SARS-CoV-2 cell entry by down-regulating SKP2 dependent ACE2 degradation. Antiviral research, 212, 105558.

Zou C, et al. (2023) The human E3 ligase RNF185 is a regulator of the SARS-CoV-2 envelope protein. iScience, 26(5), 106601.

Yang Z, et al. (2023) Repurposing niclosamide as a novel anti-SARS-Cov-2 drug by restricting entry protein CD147. Research square.

Li F, et al. (2023) A spike-targeting bispecific T cell engager strategy provides dual layer protection against SARS-CoV-2 infection in vivo. Communications biology, 6(1), 592.

Walter M, et al. (2022) SIRT5 is a proviral factor that interacts with SARS-CoV-2 Nsp14 protein. bioRxiv : the preprint server for biology.